ND Biosciences

Publications on Protein Engineering Technologies
Related to Parkinson’s Disease

  • Dikiy I, Fauvet B, Jovičić A, Mahul-Mellier A, Desorby C, El-Turk F, Gitler AD, Lashuel HA, Eliezer D. Semisynthetic and in vitro phosphorylation of alpha-synuclein at Y39 promotes functional partly-helical membrane-bound states resembling those induced by PD mutations. ACS Chem Biol. 2016, 11(9):2428-37.
  • Fauvet B and Lashuel HA. Semisynthesis and enzymatic preparation of post-translationally modified α-Synuclein. Methods in Molecular Biology. 2016, 1345:3-20.
  • Fauvet B, Butterfield SM, Fuks J, Brik A, and Lashuel HA. One-pot total chemical synthesis of alpha-synulein. Chem Commu. 2013, 49 (81), 9254 – 9256.
  • Haj-Yahia M, Fauvet B, Herman-Badhinsky Y, Hejjaoui M, Bavikar SN, Vedhanarayanan K, Ciechanover A, Lashuel HA and Brik A. Synthetic polyubiquitin alpha-synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology., Proceedings of the National Academy of Sciences. 2013, 110(44):17726-31
  • Hejjaoui M, Butterfield S, Fauvet B, Vercryusse F, Cun J, Dikiy I, Prudent M, Olschewski D, Zhang Y, Eliezer D, Lashuel HA.  Chemical Biology of α-synuclein: Elucidating the role of C-terminal post-translational modifications using protein semisynthetic strategies: Phosphorylation at Tyrosine 125. Journal of the American Chemical Society. 2012. 21;134(11):5196-210.
  • Fauvet B, Fares BM, Samuel F, Kikiy I, Tandon A, Eliezer D, Lashuel HA. Characterization of semisynthetic and natural N-terminal acetylated α-synuclein in vitro and in intact cells: Iimplications for a-synuclein aggregation and cellular properties. Journal of Biological Chemistry. 2012, 17;287(34):28243-62.
  • Hejjaoui H, Haj-Yahya M, Kumar KS, Brik A, Lashuel HA. Towards elucidating the role of ubiquitination in the pathogenesis of Parkinson’s disease using semisynthetic ubquitinated α-synuclein. Angewandte Chem Int Ed. 2011, 10;50(2):405-9.